Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...